◼ Archived
Business
🔮 fades ✓
Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial
Bristol Myers Squibb stock rises as its blood cancer cell therapy succeeds in a mid-stage trial.
3 trends tracked about this subject — the full history, oldest to newest below.
Bristol Myers Squibb stock rises as its blood cancer cell therapy succeeds in a mid-stage trial.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.